敗血症診断の世界市場 - 2024年～2031年

レポート概要

敗血症診断の世界市場は、2023年に7億1,013万米ドルに達し、2031年には14億3,524万米ドルに達すると予測され、予測期間2024年～2031年のCAGRは9.5%で成長する見込みです。

敗血症は、身体の免疫系が感染症に過剰に反応し、臓器の機能不全を引き起こすことで発生する、生命を脅かす病気です。身体の反応は組織や臓器にダメージを与え、迅速に発見し治療しなければショック、多臓器不全、さらには死に至ることもあります。

血液検査や、尿、傷口からの液体、粘液、気道からの唾液などのその他の検査項目が、この病態を診断するために実施されます。

市場力学：

促進要因と抑制要因

感染症負担の増大

感染症を速やかに発見し治療しなければ、敗血症のような重篤な状態に発展する可能性があります。そのため、敗血症に発展する可能性のある感染症の早期診断が重視されています。敗血症の診断検査は、ヘルスケアプロバイダーが病態を早期に発見し、適切な介入と管理を可能にするのに役立ちます。HAIは院内感染であり、敗血症の大きな原因となります。

ヘルスケア関連感染症が増加の一途をたどる中、このような環境で患者をモニタリングし、敗血症を早期に診断するための正確な診断ツールの必要性が高まっています。

欧州では、最も頻度の高い6つのHAIの負担は、身体障害と早期死亡という点で、他の32の感染症全体の負担の2倍になると計算されています。

さらに、2023年Balasubramanianらによって発表された調査によると、世界中で毎年推定1億3,600万件のヘルスケア関連抗生物質耐性感染症が発生しています。このように、感染症負担の増大は市場成長の原動力になると予想されます。

診断ツールの高コスト

自動診断機器やバイオマーカー検査は高額になる可能性があります。初期費用が高額になると、医療施設での全体的な導入率が低下する可能性があります。これは敗血症診断市場の成長鈍化に直結します。このような制約があるにもかかわらず、病院はより安価な旧来の方法を使い続けると思われます。

目次

第1章 調査手法と調査範囲

第2章 定義と概要

第3章 エグゼクティブサマリー

第4章 市場力学

• 影響要因
  • 促進要因
    • 感染症負担の増大
  • 抑制要因
    • 診断ツールの高コスト
  • 機会
  • 影響分析

第5章 産業分析

• ポーターのファイブフォース分析
• サプライチェーン分析
• 価格分析
• 規制分析
• 償還分析
• 特許分析
• SWOT分析
• DMIオピニオン

第6章 製品別

• 医療機器
• ソフトウェア
• 血液培養培地
• アッセイ・試薬
• その他

第7章 技術別

• フローサイトメトリー
• 微生物学
• バイオマーカー
• 分子診断学
• マイクロフルイディクス
• その他

第8章 診断方法別

• 自動診断
• 従来型診断法

第9章 病原菌別

• 真菌性敗血症
• 細菌性敗血症
  • グラム陽性菌性敗血症
  • グラム陰性菌性敗血症
• その他

第10章 エンドユーザー別

• 病院
• 病理・レファレンスラボラトリー
• その他

第11章 地域別

• 北米
  • 米国
  • カナダ
  • メキシコ
• 欧州
  • ドイツ
  • 英国
  • フランス
  • イタリア
  • スペイン
  • その他欧州
• 南米
  • ブラジル
  • アルゼンチン
  • その他南米
• アジア太平洋
  • 中国
  • インド
  • 日本
  • オーストラリア
  • その他アジア太平洋
• 中東・アフリカ

第12章 競合情勢

• 競合シナリオ
• 市況/シェア分析
• M&A分析

第13章 企業プロファイル

• Thermo Fisher Scientific Inc.
  • 会社概要
  • 製品ポートフォリオと説明
  • 財務概要
  • 主な発展
• Bruker Corporation
• Merck Millipore
• Siemens Healthineers
• Becton, Dickinson, and Company
• Hoffmann-LA Roche Ltd
• T2 Biosystems, Inc.
• Response Biomedical Corp.
• BioMerieux SA
• Immunexpress Inc.（LIST NOT EXHAUSTIVE）

第14章 付録

Report Overview

The Global Sepsis Diagnostics Market reached US$ 710.13 million in 2023 and is expected to reach US$ 1,435.24 million by 2031, growing at a CAGR of 9.5% during the forecast period 2024-2031.

Sepsis is a life-threatening illness that occurs when the body's immune system overreacts to an infection, causing organ malfunction. The body's response damages its tissues and organs, which can result in shock, multiple organ failure, and even death if not detected and treated swiftly.

Blood tests and other lab tests such as urine, liquid from the wound, mucus, and saliva from the respiratory tract are performed to diagnose the condition.

Market Dynamics: Drivers & Restraints

The growing burden of infectious diseases

If infectious infections are not detected and treated promptly, they can develop into serious conditions such as sepsis. As a result, there is a greater emphasis on early diagnosis of infections that could develop into sepsis. Diagnostic tests for sepsis assist healthcare providers in detecting the condition early, allowing for appropriate intervention and management. HAIs are hospital-acquired infections that can significantly contribute to sepsis cases.

As healthcare-associated infections continue to rise, there is a greater need for precise diagnostic tools to monitor patients and diagnose sepsis early in these settings.

In Europe, the burden of the six most frequent HAIs was calculated to be twice the burden of 32 other infectious diseases altogether, in terms of disability and premature mortality.

Additionally, according to research published by 2023 Balasubramanian et al., an estimated 136 million cases of healthcare-associated antibiotic-resistant infections occur worldwide every year. Thus, the increasing burden of infectious diseases is expected to drive the market growth.

High Cost of Diagnostic Tools

Automated diagnostic instruments and biomarker tests can be costly. High upfront expenses could result in a slower overall adoption rate among medical facilities. This directly translates into slower growth in the sepsis diagnostics market. Despite these limitations, hospitals will continue to use older, less expensive methods.

Segment Analysis

The global sepsis diagnostic market is segmented based on product, technology, diagnostic method, pathogen, end-user and region.

Blood Culture Media segment is expected to dominate the market growth

Blood culture media is expected to be the dominant segment in the sepsis diagnostics market. Blood culture media is a less expensive diagnostic technique than other approaches such as molecular diagnostics. Blood culture media is readily accessible and simple in most therapeutic settings.

While more rapid approaches are emerging, blood cultures remain the accepted standard for identifying the specific pathogens causing sepsis since they allow for the growth and identification of bacteria or fungi. Thus, the above factors are expected to hold the segment in the dominant position.

Geographical Analysis

North America is expected to hold a significant position in the sepsis diagnostic market share

North America is expected to dominate the sepsis diagnostic market owing to the increasing prevalence of sepsis and the technological advancements in sepsis diagnosis such as advanced diagnostic facilities and high adoption rates of medical technologies are expected to drive the market growth in the region. The medical diagnostic companies in the region are introducing several tests and the required sepsis diagnostic tools which could help in driving the market growth.

Foe instance, in August 2023, Medical diagnostic company Cytovale commercially introduced its new diagnostic tool, the IntelliSep sepsis test, in the US. The test was launched following 510(k) clearance from the US Food and Drug Administration in December 2022.

Additionally, on April 3, 2024, Prenosis, Inc. received the U.S. Food and Drug Administration (FDA) approval of the marketing authorization for the Sepsis ImmunoScoreTM using the De Novo pathway. The Sepsis ImmunoScoreTM is an artificial intelligence/machine learning software as a medical device (AI SaMD) to guide rapid diagnosis and prediction of sepsis. Thus, the above factors are expected to hold the region in the dominant position.

Market Segmentation

By Product

Instruments

Software

Blood Culture Media

Assays & Reagents

Others

By Technology

Flow Cytometry

Microbiology

Biomarkers

Molecular Diagnostics

Microfluidics

Others

By Pathogen

Automated Diagnostics

Conventional Diagnostics

By Diagnostic Method

Fungal Sepsis

Bacterial Sepsis

Gram-Positive Bacterial Sepsis

Gram-Negative Bacterial Sepsis

Other Pathogens

By End-User

Hospitals

Pathology & Reference Laboratories

Others

By Region

North America

U.S.

Canada

Mexico

Europe

Germany

UK

France

Italy

Spain

Rest of Europe

South America

Brazil

Argentina

Rest of South America

Asia-Pacific

China

India

Japan

Australia

Rest of Asia-Pacific

Middle East and Africa

Competitive Landscape

The major global players in the market include Thermo Fisher Scientific Inc., Bruker Corporation, Merck Millipore, Siemens Healthineers, Becton, Dickinson, and Company, Hoffmann-LA Roche Ltd, T2 Biosystems, Inc., Response Biomedical Corp., BioMerieux SA, and Immunexpress Inc. among others.

Key Developments

On April 18, 2023, Carle Illinois College of Medicine faculty member Rashid Bashir received marketing approval from the Food and Drug Administration for A new AI tool for sepsis diagnosis developed from research.

On November 27, 2023, Asep Medical Holdings Inc. secured patent approval in the US for its AI-based sepsis diagnostic technology, SepsetER.

Why Purchase the Report?

To visualize the global Sepsis Diagnostic market segmentation based on Product, Technology, Diagnostic Method, Pathogen and End-User and region as well as understand key commercial assets and players.

Identify commercial opportunities by analyzing trends and co-development.

Excel data sheet with numerous data points of Sepsis Diagnostic market-level with all segments.

PDF report consists of a comprehensive analysis after exhaustive qualitative interviews and an in-depth study.

Product mapping available as excel consisting of key products of all the major players.

The global Sepsis Diagnostic market report would provide approximately 53 tables, 47 figures and 176 pages.

Target Audience 2024

Manufacturers/ Buyers

Industry Investors/Investment Bankers

Research Professionals

Emerging Companies

Table of Contents

1. Methodology and Scope

• 1.1. Research Methodology
• 1.2. Research Objective and Scope of the Report

2. Definition and Overview

3. Executive Summary

• 3.1. Snippet by Product
• 3.2. Snippet by Technology
• 3.3. Snippet by Diagnostic Method
• 3.4. Snippet by Technology
• 3.5. Snippet by End-User
• 3.6. Snippet by Region

4. Dynamics

• 4.1. Impacting Factors
  • 4.1.1. Drivers
    • 4.1.1.1. Growing burden of infectious diseases
  • 4.1.2. Restraints
    • 4.1.2.1. High cost of diagnostic tools
  • 4.1.3. Opportunity
  • 4.1.4. Impact Analysis

5. Industry Analysis

• 5.1. Porter's Five Force Analysis
• 5.2. Supply Chain Analysis
• 5.3. Pricing Analysis
• 5.4. Regulatory Analysis
• 5.5. Reimbursement Analysis
• 5.6. Patent Analysis
• 5.7. SWOT Analysis
• 5.8. DMI Opinion

6. By Product

• 6.1. Introduction
  • 6.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Product
  • 6.1.2. Market Attractiveness Index, By Product
• 6.2. Instruments *
  • 6.2.1. Introduction
  • 6.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)
• 6.3. Software
• 6.4. Blood Culture Media
• 6.5. Assays & Reagents
• 6.6. Others

7. By Technology

• 7.1. Introduction
  • 7.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Technology
  • 7.1.2. Market Attractiveness Index, By Technology
• 7.2. Flow Cytometry*
  • 7.2.1. Introduction
  • 7.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)
• 7.3. Microbiology
• 7.4. Biomarkers
• 7.5. Molecular Diagnostics
• 7.6. Microfluidics
• 7.7. Others

8. By Diagnostic Method

• 8.1. Introduction
  • 8.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Diagnostic Method
  • 8.1.2. Market Attractiveness Index, By Diagnostic Method
• 8.2. Automated Diagnostics*
  • 8.2.1. Introduction
  • 8.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)
• 8.3. Conventional Diagnostics

9. By Pathogen

• 9.1. Introduction
  • 9.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Pathogen
  • 9.1.2. Market Attractiveness Index, By Pathogen
• 9.2. Fungal Sepsis*
  • 9.2.1. Introduction
  • 9.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)
• 9.3. Bacterial Sepsis
  • 9.3.1. Gram-Positive Bacterial Sepsis
  • 9.3.2. Gram-Negative Bacterial Sepsis
• 9.4. Other Pathogens

10. By End-User

• 10.1. Introduction
  • 10.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By End-User
  • 10.1.2. Market Attractiveness Index, By End-User
• 10.2. Hospitals*
  • 10.2.1. Introduction
  • 10.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)
• 10.3. Pathology & Reference Laboratories
• 10.4. Others

11. By Region

• 11.1. Introduction
  • 11.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Region
  • 11.1.2. Market Attractiveness Index, By Region
• 11.2. North America
  • 11.2.1. Introduction
  • 11.2.2. Key Region-Specific Dynamics
    • 11.2.2.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Product
    • 11.2.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%), By Technology
  • 11.2.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Diagnostic Method
    • 11.2.3.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Pathogen
    • 11.2.3.2. Market Size Analysis and Y-o-Y Growth Analysis (%), By End-User
  • 11.2.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
    • 11.2.4.1. U.S.
    • 11.2.4.2. Canada
    • 11.2.4.3. Mexico
• 11.3. Europe
  • 11.3.1. Introduction
  • 11.3.2. Key Region-Specific Dynamics
    • 11.3.2.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Product
    • 11.3.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%), By Technology
  • 11.3.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Diagnostic Method
    • 11.3.3.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Pathogen
  • 11.3.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By End-User
  • 11.3.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
    • 11.3.5.1. Germany
    • 11.3.5.2. UK
    • 11.3.5.3. France
    • 11.3.5.4. Italy
    • 11.3.5.5. Spain
    • 11.3.5.6. Rest of Europe
• 11.4. South America
  • 11.4.1. Introduction
  • 11.4.2. Key Region-Specific Dynamics
    • 11.4.2.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Product
    • 11.4.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%), By Technology
  • 11.4.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Diagnostic Method
    • 11.4.3.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Pathogen
  • 11.4.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By End-User
  • 11.4.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
    • 11.4.5.1. Brazil
    • 11.4.5.2. Argentina
    • 11.4.5.3. Rest of South America
• 11.5. Asia-Pacific
  • 11.5.1. Introduction
  • 11.5.2. Key Region-Specific Dynamics
    • 11.5.2.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Product
    • 11.5.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%), By Technology
  • 11.5.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Diagnostic Method
    • 11.5.3.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Pathogen
  • 11.5.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By End-User
  • 11.5.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
    • 11.5.5.1. China
    • 11.5.5.2. India
    • 11.5.5.3. Japan
    • 11.5.5.4. Australia
    • 11.5.5.5. Rest of Asia-Pacific
• 11.6. Middle East and Africa
  • 11.6.1. Introduction
  • 11.6.2. Key Region-Specific Dynamics
    • 11.6.2.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Product
    • 11.6.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%), By Technology
  • 11.6.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Diagnostic Method
    • 11.6.3.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Pathogen
    • 11.6.3.2. Market Size Analysis and Y-o-Y Growth Analysis (%), By End-User

12. Competitive Landscape

• 12.1. Competitive Scenario
• 12.2. Market Positioning/Share Analysis
• 12.3. Mergers and Acquisitions Analysis

13. Company Profiles

• 13.1. Thermo Fisher Scientific Inc.*
  • 13.1.1. Company Overview
  • 13.1.2. Product Portfolio and Description
  • 13.1.3. Financial Overview
  • 13.1.4. Key Developments
• 13.2. Bruker Corporation
• 13.3. Merck Millipore
• 13.4. Siemens Healthineers
• 13.5. Becton, Dickinson, and Company
• 13.6. Hoffmann-LA Roche Ltd
• 13.7. T2 Biosystems, Inc.
• 13.8. Response Biomedical Corp.
• 13.9. BioMerieux SA
• 13.10. Immunexpress Inc. (LIST NOT EXHAUSTIVE)

14. Appendix

• 14.1. About Us and Services
• 14.2. Contact Us